10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Anti-CTLA-4 / CD152 Reference Antibody (ipilimumab)

Recombinant Antibody
Catalog # APR10859

Product Information


Application	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P16410
Clonality	Monoclonal
Isotype	Human IgG1
Calculated MW	145 KDa

Additional Information


Target/Specificity	CTLA-4 / CD152
Endotoxin	
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Protein Information


Images




Anti- Human CTLA-4(Ipilimumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.



The purity of Anti- Human CTLA-4(Ipilimumab) is 99.37%, determined by SEC-HPLC.



Human CTLA-4 & PD-1-expressing CHO-K cells were stained with Anti- Human CTLA-4(Ipilimumab), with isotype and secondary-only controls. Flow analysis showed specific binding of the antibody, with an EC50 of 0.2270 ug/mL.



Anti- Human CTLA-4(Ipilimumab)inhibited the tumor growth of MC38 on huCTLA-4 mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 99.3% at 0.88 mpk at D37.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.